analyst day present guidanc bracket con
attend analyst meet dana point california note number
meaning updat signific around compani long-term
guidanc given first time stock pressur
today think due market pressur growth name
similarli under-perform one thing investor hope
get like clariti tangibl revenu target around
opportun verili provid longer term revenu margin target
revenu goal bracket consensu
repres growth rate time count
growth current core intens market impli doubl
current penetr vs patient core market
give complet visibl price acknowledg pharmaci channel could
bring price pressur signific margin opportun
ebitda guidanc consensu although focu remain rev
margin target given number street base case
posit sure signific leverag opportun scale autom
reduct support back end stage think investor focu primarili
revenu growth valu compani pt base revenu base
case indic compel growth margin opportun next
year stage see much base case bake need
confid futur area upsid posit
recent launch coverag read analysi ub evid lab survey
remind recent launch coverag neutral rate
pt pleas see report link includ analysi data two ub
evid lab survey physician treat diabet patient patient diabet
valuat price base sale
trade revenu rebound trough year ago
back sever quarter strong growth peer similar
growth reflect good market exposur lead product execut
trade data key metric
compani account thomson reuter ub estim ub adjust ep state goodwill-rel charg adjust abnorm econom item analyst
judgement valuat base averag share price year base share price dec estimate
report prepar ub secur llc except core rate band page analyst certif
requir disclosur begin page ub seek busi compani cover research
report result investor awar firm may conflict interest could affect object
report investor consid report singl factor make invest decis
ub research thesi map guid think report
 us cgm market grow high twenti next two year
ye ub evid lab diabet survey plural call growth us cgm market
next two year versu compani estim us consensu growth
 dexcom grow cgm market rate
data say necessarili bad thing market growth robust ub
evid lab survey suggest like gain share vote
physician respond respect note grow smaller cgm base
like consensu view
 risk cgm price reimburs player enter market
unclear patient survey unhappi diabet cost physician seem think could
price/reimburs cut competit price cut payer gener
desir pay less thing think market bake lsd pressur
neutral rate base view strong product growth momentum
healthi cgm market mostli reflect share sale see potenti upsid
consensu think buy side alreadi risk includ competit price cut
balanc enthusiasm busi level
analysi ub evid lab diabet survey plural physician patient suggest cgm
market growth compani project high look like
gain share rank well overal technolog vector like accuraci eas
use patient gener happi cgm devic
share re-rat revenu vs trough year ago follow sever
quarter acceler growth consensu estim call growth
upsid downsid
compani descript dexcom medic devic compani primarili focus design develop
commerci continu glucos monitor system use peopl diabet
get revenu rang factor
revenu adjac opportun simpli base increas
penetr insulin intens market number factor
financi figur includ number larg adjac market outsid
core intens busi patient us doubl
emea row includ emerg market
contempl anyth gestat market hospit market
non-intens pre-diabet patient
assum growth rate us ballpark ou
figur annual lrp guidanc compar consensu ubs
impli compound-annual-growth-rate use low end
figur think improv oper margin bp
ebitda bp includ sbc time-frame volum growth
expect grow even faster make profit
margin profit dollar pharmaci channel versu dme channel despit
lower revenu per patient also excit coverag
see addit patient good candid cgm
coverag margin front start move path
profit compani will take foot ga pedal
area drive growth continu reinvest growth opportun
knowledg om upsid beyond
refer peer om
oper margin target street model
 bridg om time look
keep gm rel flat primari driver increas
profit reinvest effort new market offset
effici gross margin line made invest new
facil az highli autom allow
scale time versu capac today grow
factor headwind off-set scale
innov bp procur excel set
procur offic within organ leverag size scale
busi deliv save
effici bp infrastructur get
revenu spent oper expens today product
capabl distribut channel effici effici includ program
design test autom offshore/nearshor effici
move pharmaci channel big sourc potenti save
dme channel get product step process take multipl
week taken day pharmaci fewer
step signific enabl help scale profit way
earli pilot see reduct work effort
reduct time process order done market research
suggest provid would increas cgm prescript pharmaci benefit
certif medic necess script anoth discreet area cost reduct
current peopl handl call per month
simpli determin order statu think much
autom still keep qualiti score high plan push
notif custom help understand order
provid updat verili partnership portfolio
recent amend verili deal strengthen product develop target
allow parti collabor next year give access
ip innov verili portfolio next year
pay equiti front mileston
remov royalti payment would run
next year agreement solidifi product timelin could
bring patch devic market updat around verili product
light detail close final design devic
upsid downsid
upsid upsid case assum achiev near growth
next two year impli minim price pressur factor
ebit margin also assum cgm market growth
base base case assum achiev growth
next two year assum slight price pressur factor ebit
margin cgm market growth high rang
downsid downsid case assum achiev high-teen
growth next two year impli moder price pressur factor
ebit margin cgm market growth
medic devic compani primarili focus
design develop commerci
continu glucos monitor system use peopl
diabet healthcar provid compani
three revenu compon sensor sale
headquart san diego california
receiv
particip diabet market provid
affect peopl global peopl
us diagnos diabet diabet classifi
type type us
type patient type
patient requir insulin type insulin intens
type patient need daili rapid-act insulin manag
diseas also need frequent glucos monitor
via either cgm finger stick part insulin
treatment global cgm market estim
grow
revenu region
revenu product segment
profit tax
profit tax
equival
invest asset
trade payabl st liabil
net incom pref div
net chang work capit
chang debt pref share
flow inc/ dec cash
balanc sheet inc/ dec cash
compani account ub estim ub metric use report figur adjust ub ep ub dilut calcul use ub net incom ad back depreci
buy minor
revenu divis us
ebit ub divis us
compani account ub estim ub metric use report figur adjust ub analyst
valuat method risk statement
price target base revenu estim
risk price target includ slowdown cgm market
competit other price reimburs risk
regulatori risk around pipelin lack insur coverag
patient margin pressur cost inflat busi execut
low cost foreign competit foreign exchang
valu abbott lab base pe
